trial · primary record
Envudeucitinib
Plaque Psoriasis
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 912 |
| Primary completion | 2025-11-20 |
| Primary endpoint | To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo |
| Registry ID | NCT06586112 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:28.341Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06586112
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Envudeucitinib · compound